Press Releases

Date Title and Summary Additional Formats
Toggle Summary Conatus Late-breaker Oral Presentation at EASL Meeting Details Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension
SAN DIEGO , April 15, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today that the company’s late-breaker oral presentation at The International Liver Congress™ 2019, the Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria
View HTML
Toggle Summary Conatus Pharmaceuticals to Participate in H.C. Wainwright Global Life Sciences Conference
SAN DIEGO , April 02, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) has accepted an invitation to participate in the H.C. Wainwright Global Life Sciences Conference ( April 7-9 in London ). Conatus senior management will conduct a series of scheduled meetings with investment
View HTML
Toggle Summary Conatus Announces Top-line Results from ENCORE-NF Phase 2b Clinical Trial in NASH Fibrosis
Shortfall on Primary Endpoint Shifts Focus for Emricasan to Ongoing NASH Cirrhosis Trials SAN DIEGO , March 21, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced top-line results from the company’s Phase 2b ENCORE-NF clinical trial in patients with biopsy-confirmed
View HTML
Toggle Summary Conatus Late-breaker Oral Presentation at EASL Meeting to Detail Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension
SAN DIEGO , March 13, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today the acceptance of an abstract for a late-breaker oral presentation at The International Liver Congress™ 2019, the Annual Meeting of the European Association for the Study of the Liver (EASL)
View HTML
Toggle Summary Conatus Pharmaceuticals Reports 2018 Financial Results and Program Updates
SAN DIEGO , March 08, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the fourth quarter and full year ended December 31, 2018 , and provided updates on its development programs. Program Updates The company is conducting three double-blind,
View HTML
Toggle Summary Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results
SAN DIEGO , March 01, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the fourth quarter and full year ended December 31, 2018 , after the market close on Friday, March 8, 2019 .
View HTML
Toggle Summary Conatus Announces Completion of Enrollment in ENCORE-LF Phase 2b Clinical Trial of Emricasan in Patients with Decompensated NASH Cirrhosis
SAN DIEGO , Feb. 12, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced the completion of enrollment in ENCORE-LF, a Phase 2b clinical trial evaluating emricasan, the company’s first-in-class, orally-active pan-caspase inhibitor.
View HTML
Toggle Summary Conatus Pharmaceuticals Announces Publications Expanding on Previously Reported Results from Completed Phase 2 NAFLD-NASH, Portal Hypertension and Liver Cirrhosis Clinical Trials
SAN DIEGO , Jan. 28, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced publications expanding on previously reported results from three of the company’s completed Phase 2 clinical trials. Mitchell Schiffman , M.D., is the lead author on a new publication 1 in
View HTML
Toggle Summary Conatus Announces Results from ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis
- Clinically Meaningful Improvements in Portal Hypertension in High Risk Compensated Cirrhosis Patients - - Conference Call and Webcast Presentation at 8:30 a.m. ET Today - SAN DIEGO , Dec. 05, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced top-line results from
View HTML
Toggle Summary Conatus Pharmaceuticals Announces Presentations and Posters at AASLD Annual Meeting
SAN DIEGO , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today the schedule of upcoming oral presentations and posters addressing clinical and preclinical results with the company’s pan-caspase inhibitor emricasan, or addressing preclinical results with
View HTML